Showing 6-10 of 95 :
OM1 and Medtronic Partner on Propel Study to Assess Long-term Outcomes for Patients With Chronic Rhinosinusitis

Utilizing clinical data from electronic health records related to endoscopic sinus surgeries, Medtronic and OM1 found PROPEL devices result in fewer postoperative care needs in chronic rhinosinusitis patients   April 09, 2024 09:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–OM1, the leading AI and insights-driven technology and data company specializing in personalized medicine, evidence generation, and[…]

Dr Joseph Zabinski Discusses Using Artificial Intelligence to Identify Patients With GPP

AJMC April 4, 2024 Read the full article and watch the video >> It is important that physicians raise awareness around the condition of generalized pustular psoriasis (GPP) in order to close the current diagnostic gap, says Joseph Zabinski, PhD, MEM, managing director of artificial intelligence (AI) and personalized medicine at OM1. Transcript How is[…]

How is Artificial Intelligence Growing Up?

Dermatology Times March 10, 2024 Kaitlyn Bader Read the full article >> At the 2024 American Academy of Dermatology Annual Meeting in San Diego, California, Joseph Zabinski, PhD, MEM, the managing director of artificial intelligence (AI) and personalized medicine at OM1, a real-world data, AI, and technology company with a focus on chronic diseases, sat down with Dermatology[…]

Integrating Ambient Clinical Voice Technology – The Impacts, Challenges, and Benefits

Healthcare IT Today March 8, 2024 Read the full article >> Joseph Zabinski, Ph.D. VP, Head of Commercial Strategy & AI at OM1 Dr. Carl Marci, Chief Clinical Officer, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1 The industry is seeing an uptick of ambient voice technologies used to help increase the efficiency,[…]

What strategies are being employed to accelerate product development and commercialization without compromising quality?

Pharma’s Almanac March 8, 2024 Read the full article >> Richard Gliklich, M.D., Chief Executive Officer, OM1, Inc. One of the most promising paths being applied to accelerate product development and commercialization comes in the form of real-world data/evidence (RWD/RWE) and applied AI. In clinical development, we are using de-identified RWD to identify clinical sites with eligible[…]